Andrey Korshunov
Andrey Korshunov is an expert in Oncology at University Hospital Heidelberg (Germany). As of October 2026, ScienceLeadR ranks Andrey Korshunov in the top 1% of experts worldwide for Glioma, Brain Neoplasms and Nervous System Neoplasms. Andrey Korshunov has authored 547 publications, the most recent in 2026, and is an investigator in 2 clinical trials. SLR score: 2,013 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Neurology - Genetics
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 2008 - 2026
Number : 547
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Divergent medulloblastoma chromatin states disclose KDM2B as a selective dependency. PMID 42786297 — genes, promoter regions, genetic, neoplasms, chromatin, medulloblastoma, dependency, psychological | Nat Genet | 2026 | 0 |
| Ependymomas are cancers of the pre-neural crest/roof plate lineage. PMID 42523223 — cells, neoplasms, ependymoma, neural crest | bioRxiv | 2026 | 0 |
| Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study. PMID 42382416 — disease-free survival, progression-free survival, multiple chronic conditions, cohort studies, classification, medulloblastoma, drug therapy, biomarkers, aged, histology, therapeutics, prognosis, infant, chemotherapy | EClinicalMedicine | 2026 | 0 |
| Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages. PMID 42236272 — brain neoplasms, cells, dna mismatch repair, glioma, giant cell tumors, neoplasms, giant cells, mmr-deficient | Neuro Oncol | 2026 | 0 |
| Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study. PMID 42150584 — craniospinal irradiation, progression-free survival, cohort studies, classification, medulloblastoma, drug therapy, biomarkers, therapeutics, pediatrics, prognosis, infant, survival rate, chemotherapy | Lancet Child Adolesc Health | 2026 | 1 |
Clinical Studies 2
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 2
LeadR Networks
Main global connection map